Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
Managing problems in treating CLL
Precision medicine, genomics and immunotherapies at ASH 2017
Molecular genetics and targeting in AML: highlights from ASH 2017
The TAMARIN study: tamoxifen for MPNs